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Background: Chromosomal instability in exfoliated urothelial cells has been associated with the development of
bladder cancer. Here, we analyzed the accumulation of copy number variations (CNVs) using fluorescence in situ
hybridization in cancer cases and explored factors associated with the detection of CNVs in tumor-free men.
Methods: The prospective UroScreen study was designed to investigate the performance of UroVysion™ and other
tumor tests for the early detection of bladder cancer in chemical workers from 2003–2010. We analyzed a database
compiling CNVs of chromosomes 3, 7, and 17 and at 9p21 that were detected in 191,434 exfoliated urothelial cells
from 1,595 men. We assessed the accumulation of CNVs in 1,400 cells isolated from serial samples that were
collected from 18 cancer cases up to the time of diagnosis. A generalized estimating equation model was applied
to evaluate the influence of age, smoking, and urine status on CNVs in cells from tumor-free men.
Results: Tetrasomy of chromosomes 3, 7 and 17, and DNA loss at 9p21 were the most frequently observed forms
of CNV. In bladder cancer cases, we observed an accumulation of CNVs that started approximately three years
before diagnosis. During the year prior to diagnosis, cells from men with high-grade bladder cancer accumulated
more CNVs than those obtained from cases with low-grade cancer (CNV < 2: 7.5% vs. 1.1%, CNV > 2: 16-17% vs.
9-11%). About 1% of cells from tumor-free men showed polysomy of chromosomes 3, 7, or 17 or DNA loss at
9p21. Men aged ≥50 years had 1.3-fold more cells with CNVs than younger men; however, we observed no further
age-related accumulation of CNVs in tumor-free men. Significantly more cells with CNVs were detected in samples with
low creatinine concentrations.
Conclusions: We found an accumulation of CNVs during the development of bladder cancer starting three years before
diagnosis, with more altered cells identified in high-grade tumors. Also, a small fraction of cells with CNVs were exfoliated
into urine of tumor-free men, mainly exhibiting tetraploidy or DNA loss at 9p21. Whether these cells are preferentially
cleared from the urothelium or are artifacts needs further exploration.
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Chromosomal instability is a common feature of tumor
cells, and has been associated with the development of
bladder cancer [1,2]. Alterations in the number of whole
chromosomes can lead to chromosomal instability due
to segregation errors [3]. For example, tetraploidization
may result from a mitotic failure [4], which can occur
early in tumorigenesis and foster the accumulation of
other forms of genomic instability [5]. Loss and gain of
DNA in certain chromosomal segments can cause struc-
tural chromosomal instability.
Although the acquisition of genomic alterations has been
recognized as a hallmark in the development of cancer, the
sequence and role of specific alterations is less clear [6].
DNA amplification in regions hosting oncogenes or the loss
of tumor suppressor genes would support the hypothesis
that structural chromosomal instability is a driving event.
However, aneuploidy has been also found to delay tumor
development [7,8]. Cells with mitotic failure could be elimi-
nated to avoid an accumulation of genomic alterations [9].
Genomic alterations have also been implicated in cel-
lular senescence that accompanies aging [10,11]. For
specific forms of alterations, such as micronuclei, accu-
mulation by age has been demonstrated [12]. Little is
known, however, about the accumulation of DNA loss
or gain at loci hosting cancer-related driver genes by age
or during cancer development [4,13,14].
Among the various methods to determine genomic al-
terations, fluorescence in situ hybridization (FISH) is com-
monly used to quantify copy number variations (CNVs),
represented as DNA loss or gain at the sequences selected
for hybridization [15]. UroVysion™ is an approved FISH
assay for bladder cancer screening that detects DNA gain
and loss of chromosomes 3, 7, and 17 and at the locus
9p21 in exfoliated urothelial cells [16,17]. The UroScreen
study was initiated to validate UroVysion™ and other
tumor tests for the early detection of bladder cancer
[18-23]. For screening purposes, the extent of genomic
alterations is commonly assessed as either positive or
negative, and the wealth of CNV data in single cells is
usually not documented.
To the best of our knowledge, UroScreen is the first pro-
spective cohort study collecting serial pre-diagnostic sam-
ples from asymptomatic subjects, which was used to
compile a CNV database with single-cell FISH results. We
took advantage of this database to explore the accumulation
of DNA gain or loss in serial pre-diagnostic samples from
cases and to investigate factors associated with the detection
of CNVs in exfoliated urothelial cells from tumor-free men.
Methods
Study population and data collection
UroScreen was a prospective screening study aimed to
validate UroVysion™ and other tumor tests for the earlydetection of bladder cancer in 1,609 active or retired
chemical workers. The study design and major results
on the performance of tumor markers have been de-
scribed elsewhere [18-20,22,23]. Here, we explored CNVs
in about 200,000 exfoliated urothelial cells from 6,517
urine samples that were collected from 1,575 cancer-free
men and 20 cases during voluntary annual screens between
2003 and 2010. A questionnaire was administered to docu-
ment smoking history and other information. The ethics
committee of the Eberhard Karls University of Tübingen,
Germany, approved the study (No. 1/2003 V). All partici-
pants gave written informed consent.Urine status and UroVysion™ assay
In freshly voided urine, creatinine was determined with
the enzymatic test CREA plus® and leukocytes, erythro-
cytes and other parameters were quantified with Combur10
Test® strips (Roche Diagnostics, Mannheim, Germany).
Additionally, erythrocytes and leukocytes were detected
microscopically in the cell segment as previously described
[22]. Urine-status data were documented for 84% of all
samples. CNVs were determined with the UroVysion™
assay according to the protocol of the manufacturer
(Abbott Laboratories, Abbott Park, IL). In brief, about
25 to 30 morphologically suspicious cells were evaluated
in each urine sediment [18]. The UroVysion™ Bladder
Cancer Kit is composed of three centromere-specific
probes (CEP 3, CEP 7, CEP 17) to capture aneusomy of
chromosomes 3, 7, and 17, and the locus-specific indicator
probe (LSI) to assess CNV at 9p21. The test was consid-
ered to be positive following the manufacturer’s decision
rule if ≥4 cells showed polysomy (CNV > 2) of ≥2 chro-
mosomes (3, 7 or 17) or if ≥12 cells had no signal at 9p21
indicating loss of both alleles (CNV = 0).Statistical analysis
We described the detailed distributions of DNA gain
and loss in terms of CNV for chromosomes 3, 7, 17 and
the 9p21 locus in about 200,000 exfoliated urothelial
cells. For the cases, we assessed the accumulation of
CNVs over time in serial pre-diagnostic samples and the
occurrence of CNVs in urine samples collected after
diagnosis of bladder cancer. In tumor-free men, we ana-
lyzed rate ratios (relative risk, expðβ^Þ) for the influence
of age (<50 years as reference), smoking status (never,
ever), haematuria, leukocytes and urinary creatinine
(<0.5 g/L, ≥0.5 g/L) on the presence of CNVs with gener-
alized estimating equation (GEE) models for repeated
measurements [24] with Poisson distribution and log link
function. The logarithm of the number of cells analyzed in
the samples was used as an offset. Calculations were per-
formed with SAS/STAT and SAS/IML software, version
9.3 (SAS Institute Inc., Cary, NC, USA).
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Characteristics of the study population of former and
active chemical workers
Table 1 describes the study population of 1,575 tumor-
free men and 20 cases who developed 21 bladder tumors
between 2003 and 2010 (13 high-grade bladder cancers,
5 low-grade bladder cancers, and 3 papillomas). In this
prospective study, one case was initially diagnosed with
a papilloma, and subsequently with high-grade bladder
cancer. The median age of tumor-free men was 62 years
(range 27–90 years) in 2010. Cases were diagnosed at a
median age of 67 years and included more ever smokers
compared to non-diseased men (75% vs. 66%).
Distribution of copy number variations by subtype of
bladder tumor
The distribution of CNVs in exfoliated urothelial cells in
the year before diagnosis is shown in Table 2, and is
stratified by subtype of bladder tumor. Notably, not all
subjects participated regularly in this annual voluntary
screening program. In exfoliated cells from cases with
papilloma, we detected no loss (CNV < 2) at 9p21, and
only a small fraction of cells (1%-2%) with tetrasomy
(CNV = 4) of chromosomes 3, 7, and 17. The samples
from the low-grade bladder cancer cases contained 9%-
11% cells with polysomy (CNV > 2) of chromosomes 3,
7, and 17, and 1% cells with loss of both alleles (CNV= 0)
at 9p21. More cells with DNA gain (CNV > 2) and DNA
loss (CNV < 2) were found in high-grade bladder cancer
cases (16%-17% and 7.5%, respectively).
Temporal accumulation of copy number variations of
chromosomes 3, 7, and 17 and at the 9p21 locus in
exfoliated urothelial cells until diagnosis of bladder
cancer
Detailed information about the distribution of CNV in
2,111 exfoliated urothelial cells from cases with bladder
cancer is shown in Table 3. We detected only two cellsTable 1 Characteristics of male active or retired workers with
Total Tu
Study participants 1,595
Age in years (median and range)
End of follow-up 62 (27 – 90) 6
At diagnosis 6




aTumor cases included three papillomas; one case developed two bladder tumors d
bThirteen high-grade and five low-grade bladder cancers.
cMissing for three tumor-free participants.with CNV = 1 of chromosome 17 in urine samples that
were collected more than three years before diagnosis.
Polysomy of chromosomes 3, 7, and 17 accumulated in
up to 14% - 15% of all cells in the year before diagnosis.
Tetrasomy (CNV = 4) was the most frequently detected
type of polysomy (6% to 8%) followed by trisomy (CNV= 3),
which was observed in 4% - 5% of all cells from the cases.
Tetrasomy of all three chromosomes (3, 7, and 17) was
observed in 3% of the cells in samples collected in the year
before diagnosis, compared to only 0.3% in tumor-free men
(data not shown). Notably, also few cells could be detected
with loss (CNV< 2) of these chromosomes that are prone to
gain. Loss of one or both alleles at 9p21 was seen in the
cases as early as two to three years before diagnosis. Also,
gain at 9p21 accumulated in up to 6% of all cells in the year
before diagnosis, compared to the even lower fraction of 4%
of cells showing a loss of both alleles at this locus. In screen-
ing rounds after diagnosis and treatment, the fraction of
cells with polysomy of chromosomes 3, 7, and 17 dropped
to 2.3% and DNA loss at 9p21 to 1.7%.Factors influencing the detection of copy number
variations of chromosomes 3, 7, and 17 and at the 9p21
locus in exfoliated urothelial cells from tumor-free men
Table 4 shows the distribution of CNVs assessed with
CEP 3, CEP 7, CEP 17, and LSI 9p21 in 188,911 exfoli-
ated urothelial cells from tumor-free men. Overall, most
cells were diploid. We observed DNA loss (CNV < 2) at
9p21 in 1.0% of all cells, and CNV > 2 at all four loci in
about 1% of all cells. CNV = 4 was the most common
type of DNA gain, found in 0.5% to 0.7% of all cells. We
observed slightly more CNVs in cells from men ≥50 years
of age compared to younger participants. For example,
the fraction of cells with polysomy of chromosome 7 was
0.9% in men aged <50 years and 1.2% in men ≥50 years
of age. The corresponding figures for age-related DNA
loss (CNV < 2) at 9p21 were 0.8% and 1.0%, respectively.
There was a small difference in DNA gain between neverformer exposure to aromatic amines
mor casesa Cancer casesb Tumor-free cases
20 18 1,575
62 (27 – 90)
8 (43 – 80) 69 (43 – 80)
7 (38 – 78) 67 (38–78)
5 (25.0) 4 (22.2) 543 (34.5)
12 (60.0) 11 (61.1) 602 (38.4)
3 (15.0) 3 (16.7) 427 (27.1)
uring UroScreen.
Table 2 Cells with copy number variations (CNVs) of chromosomes 3, 7, 17 and at 9p21 in cases by subtype of bladder
tumor in urine samples collected in the year before diagnosis
CNV 0 1 2 3 4 ≥5 Total Loss (CNV <2) Gain (CNV >2)
All cases CEP 3 N (%) 2 (0.3) 0 (0) 554 (87.4) 26 (4.1) 37 (5.8) 15 (2.4) 634 (100) 2 (0.3) 78 (12.3)
CEP 7 N (%) 2 (0.3) 2 (0.3) 547 (86.3) 26 (4.1) 46 (7.3) 11 (1.7) 634 (100) 4 (0.6) 83 (13.1)
CEP 17 N (%) 2 (0.3) 3 (0.5) 552 (87.1) 24 (3.8) 35 (5.5) 18 (2.8) 634 (100) 5 (0.8) 77 (12.1)
LSI 9p21 N (%) 22 (3.5) 8 (1.3) 567 (89.4) 15 (2.4) 21 (3.3) 1 (0.2) 634 (100) 30 (4.7) 37 (5.8)
Papilloma (2 cases, 3 samples) CEP 3 N (%) 0 (0) 0 (0) 83 (97.6) 0 (0) 2 (2.4) 0 (0) 85 (100) 0 (0) 2 (2.4)
CEP 7 N (%) 0 (0) 1 (1.2) 83 (97.6) 0 (0) 1 (1.2) 0 (0) 85 (100) 1 (1.2) 1 (1.2)
CEP 17 N (%) 0 (0) 0 (0) 83 (97.6) 0 (0) 2 (2.4) 0 (0) 85 (100) 0 (0) 2 (2.4)
LSI 9p21 N (%) 0 (0) 0 (0) 83 (97.6) 1 (1.2) 1 (1.2) 0 (0) 85 (100) 0 (0) 2 (2.4)
Low-grade bladder cancer
(5 cases, 6 samples)
CEP 3 N (%) 0 (0) 0 (0) 159 (90.9) 3 (1.7) 7 (4.0) 6 (3.4) 175 (100) 0 (0) 16 (9.1)
CEP 7 N (%) 0 (0) 0 (0) 156 (89.1) 8 (4.6) 7 (4.0) 4 (2.3) 175 (100) 0 (0) 19 (10.9)
CEP 17 N (%) 0 (0) 0 (0) 160 (91.4) 7 (4.0) 5 (2.9) 3 (1.7) 175 (100) 0 (0) 15 (8.6)
LSI 9p21 N (%) 2 (1.1) 0 (0) 163 (93.1) 7 (4.0) 3 (1.7) 0 (0) 175 (100) 2 (1.1) 10 (5.7)
High-grade bladder cancer
(9 cases, 12 samples)
CEP 3 N (%) 2 (0.5) 0 (0) 312 (83.4) 23 (6.1) 28 (7.5) 9 (2.4) 374 (100) 2 (0.5) 60 (16.0)
CEP 7 N (%) 2 (0.5) 1 (0.3) 308 (82.4) 18 (4.8) 38 (10.2) 7 (1.9) 374 (100) 3 (0.8) 63 (16.8)
CEP 17 N (%) 2 (0.5) 3 (0.8) 309 (82.6) 17 (4.5) 28 (7.5) 15 (4.0) 374 (100) 5 (1.3) 60 (16.0)
LSI 9p21 N (%) 20 (5.3) 8 (2.1) 321 (85.8) 7 (1.9) 17 (4.5) 1 (0.3) 374 (100) 28 (7.5) 25 (6.7)
Table 3 Cells with copy number variations (CNVs) of chromosomes 3, 7, 17 and at 9p21 in urines from 18 cases with
bladder cancer
CNV 0 1 2 3 4 ≥5 Total Loss (CNV <2) Gain (CNV >2)
>3 years before diagnosis CEP 3 N (%) 0 (0) 0 (0) 350 (100) 0 (0) 0 (0) 0 (0) 350 (100) 0 (0) 0 (0)
CEP 7 N (%) 0 (0) 0 (0) 350 (100) 0 (0) 0 (0) 0 (0) 350 (100) 0 (0) 0 (0)
CEP 17 N (%) 0 (0) 2 (0.6) 348 (99.4) 0 (0) 0 (0) 0 (0) 350 (100) 2 (0.6) 0 (0)
LSI 9p21 N (%) 0 (0) 0 (0) 350 (100) 0 (0) 0 (0) 0 (0) 350 (100) 0 (0) 0 (0)
>2 - 3 years before diagnosis CEP 3 N (%) 0 (0) 0 (0) 197 (88.3) 9 (4.0) 12 (5.4) 5 (2.2) 223 (100) 0 (0) 26 (11.7)
CEP 7 N (%) 0 (0) 1 (0.4) 198 (88.8) 10 (4.5) 9 (4.0) 5 (2.2) 223 (100) 1 (0.4) 24 (10.8)
CEP 17 N (%) 0 (0) 0 (0) 198 (88.8) 8 (3.6) 10 (4.5) 7 (3.1) 223 (100) 0 (0) 25 (11.2)
LSI 9p21 N (%) 21 (9.4) 3 (1.3) 198 (88.8) 0 (0) 1 (0.4) 0 (0) 223 (100) 24 (10.8) 1 (0.4)
>1 - 2 years before diagnosis CEP 3 N (%) 0 (0) 0 (0) 256 (92.1) 7 (2.5) 14 (5.0) 1 (0.4) 278 (100) 0 (0) 22 (7.9)
CEP 7 N (%) 0 (0) 1 (0.4) 257 (92.4) 6 (2.2) 13 (4.7) 1 (0.4) 278 (100) 1 (0.4) 20 (7.2)
CEP 17 N (%) 0 (0) 3 (1.1) 255 (91.7) 5 (1.8) 14 (5.0) 1 (0.4) 278 (100) 3 (1.1) 20 (7.2)
LSI 9p21 N (%) 12 (4.3) 5 (1.8) 256 (92.1) 2 (0.7) 3 (1.1) 0 (0) 278 (100) 17 (6.1) 5 (1.8)
≤1 year before diagnosis CEP 3 N (%) 2 (0.4) 0 (0) 471 (85.8) 26 (4.7) 35 (6.4) 15 (2.7) 549 (100) 2 (0.4) 76 (13.8)
CEP 7 N (%) 2 (0.4) 1 (0.2) 464 (84.5) 26 (4.7) 45 (8.2) 11 (2.0) 549 (100) 3 (0.5) 82 (14.9)
CEP 17 N (%) 2 (0.4) 3 (0.5) 469 (85.4) 24 (4.4) 33 (6.0) 18 (3.3) 549 (100) 5 (0.9) 75 (13.7)
LSI 9p21 N (%) 22 (4.0) 8 (1.5) 484 (88.2) 14 (2.6) 20 (3.6) 1 (0.2) 549 (100) 30 (5.5) 35 (6.4)
After diagnosis CEP 3 N (%) 0 (0) 0 (0) 695 (97.7) 3 (0.4) 7 (1.0) 6 (0.8) 711 (100) 0 (0) 16 (2.3)
CEP 7 N (%) 0 (0) 1 (0.1) 694 (97.6) 3 (0.4) 7 (1.0) 6 (0.8) 711 (100) 1 (0.1) 16 (2.3)
CEP 17 N (%) 0 (0) 1 (0.1) 694 (97.6) 2 (0.3) 5 (0.7) 9 (1.3) 711 (100) 1 (0.1) 16 (2.3)
LSI 9p21 N (%) 10 (1.4) 2 (0.3) 695 (97.7) 1 (0.1) 3 (0.4) 0 (0) 711 (100) 12 (1.7) 4 (0.6)
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Table 4 Cells with copy number variations (CNVs) of chromosomes 3, 7, and 17 and at 9p21 in urines from 1,575
tumor-free men
CNV Locus 0 1 2 3 4 ≥5 Total Loss (CNV <2) Gain (CNV >2)
Total CEP 3 N (%) 130 (0.1) 260 (0.1) 186508 (98.7) 549 (0.3) 1313 (0.7) 151 (0.1) 188911 (100) 390 (0.2) 2013 (1.1)
CEP 7 N (%) 5 (0) 327 (0.2) 186430 (98.7) 702 (0.4) 1317 (0.7) 130 (0.1) 188911 (100) 332 (0.2) 2149 (1.1)
CEP 17 N (%) 114 (0.1) 907 (0.5) 186242 (98.6) 657 (0.3) 904 (0.5) 87 (0.0) 188911 (100) 1021 (0.5) 1648 (0.9)
LSI 9p21 N (%) 736 (0.4) 1089 (0.6) 185417 (98.2) 431 (0.2) 1156 (0.6) 82 (0.0) 188911 (100) 1825 (1.0) 1669 (0.9)
Age (years)a
<50 CEP 3 N (%) 32 (0.1) 62 (0.1) 47873 (98.9) 136 (0.3) 251 (0.5) 29 (0.1) 48383 (100) 94 (0.2) 416 (0.9)
CEP 7 N (%) 1 (0.0) 80 (0.2) 47861 (98.9) 151 (0.3) 257 (0.5) 33 (0.1) 48383 (100) 81 (0.2) 441 (0.9)
CEP 17 N (%) 15 (0.0) 192 (0.4) 47854 (98.9) 137 (0.3) 167 (0.3) 18 (0.0) 48383 (100) 207 (0.4) 322 (0.7)
LSI 9p21 N (%) 162 (0.3) 230 (0.5) 47638 (98.5) 77 (0.2) 248 (0.5) 28 (0.1) 48383 (100) 392 (0.8) 353 (0.7)
≥50 CEP 3 N (%) 98 (0.1) 198 (0.1) 138635 (98.7) 413 (0.3) 1062 (0.8) 122 (0.1) 140528 (100) 296 (0.2) 1597 (1.1)
CEP 7 N (%) 4 (0.0) 247 (0.2) 138569 (98.6) 551 (0.4) 1060 (0.8) 97 (0.1) 140528 (100) 251 (0.2) 1708 (1.2)
CEP 17 N (%) 99 (0.1) 715 (0.5) 138388 (98.5) 520 (0.4) 737 (0.5) 69 (0.0) 140528 (100) 814 (0.6) 1326 (0.9)
LSI 9p21 N (%) 574 (0.4) 859 (0.6) 137779 (98.0) 354 (0.3) 908 (0.6) 54 (0.0) 140528 (100) 1433 (1.0) 1316 (0.9)
Smoking
Never CEP 3 N (%) 37 (0.1) 91 (0.2) 51871 (98.8) 140 (0.3) 320 (0.6) 33 (0.1) 52492 (100) 128 (0.2) 493 (0.9)
CEP 7 N (%) 1 (0.0) 92 (0.2) 51865 (98.8) 198 (0.4) 312 (0.6) 24 (0.0) 52492 (100) 93 (0.2) 534 (1.0)
CEP 17 N (%) 31 (0.1) 258 (0.5) 51808 (98.7) 147 (0.3) 230 (0.4) 18 (0.0) 52492 (100) 289 (0.6) 395 (0.8)
LSI 9p21 N (%) 199 (0.4) 307 (0.6) 51556 (98.2) 106 (0.2) 302 (0.6) 22 (0.0) 52492 (100) 506 (1.0) 430 (0.8)
Ever CEP 3 N (%) 93 (0.1) 169 (0.1) 134637 (98.7) 409 (0.3) 993 (0.7) 118 (0.1) 136419 (100) 262 (0.2) 1520 (1.1)
CEP 7 N (%) 4 (0.0) 235 (0.2) 134565 (98.6) 504 (0.4) 1005 (0.7) 106 (0.1) 136419 (100) 239 (0.2) 1615 (1.2)
CEP 17 N (%) 83 (0.1) 649 (0.5) 134434 (98.5) 510 (0.4) 674 (0.5) 69 (0.1) 136419 (100) 732 (0.5) 1253 (0.9)
LSI 9p21 N (%) 537 (0.4) 782 (0.6) 133861 (98.1) 325 (0.2) 854 (0.6) 60 (0.0) 136419 (100) 1319 (1.0) 1239 (0.9)
Creatinine (g/L)a
<0.5 CEP 3 N (%) 25 (0.1) 42 (0.2) 24377 (98.0) 129 (0.5) 254 (1.0) 39 (0.2) 24866 (100) 67 (0.3) 422 (1.7)
CEP 7 N (%) 1 (0.0) 43 (0.2) 24361 (98.0) 142 (0.6) 273 (1.1) 46 (0.2) 24866 (100) 44 (0.2) 461 (1.9)
CEP 17 N (%) 21 (0.1) 159 (0.6) 24361 (98.0) 142 (0.6) 155 (0.6) 28 (0.1) 24866 (100) 180 (0.7) 325 (1.3)
LSI 9p21 N (%) 135 (0.5) 166 (0.7) 24205 (97.3) 88 (0.4) 248 (1.0) 24 (0.1) 24866 (100) 301 (1.2) 360 (1.4)
≥0.5 CEP 3 N (%) 56 (0.0) 166 (0.1) 134228 (98.9) 356 (0.3) 865 (0.6) 78 (0.1) 135749 (100) 222 (0.2) 1299 (1.0)
CEP 7 N (%) 4 (0.0) 227 (0.2) 134144 (98.8) 439 (0.3) 864 (0.6) 71 (0.1) 135749 (100) 231 (0.2) 1374 (1.0)
CEP 17 N (%) 60 (0.0) 572 (0.4) 134036 (98.7) 424 (0.3) 614 (0.5) 43 (0.0) 135749 (100) 632 (0.5) 1081 (0.8)
LSI 9p21 N (%) 456 (0.3) 708 (0.5) 133478 (98.3) 285 (0.2) 770 (0.6) 52 (0.0) 135749 (100) 1164 (0.9) 1107 (0.8)
aSamples from one person collected at different time points could be allocated into two different groups, due to the longitudinal design of the UroScreen study.
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http://www.biomedcentral.com/1471-2407/14/854and ever smokers. The fraction of cells with polysomy of
chromosome 7 was 0.9% in never smokers and 1.1% in
ever smokers. No such difference was observed for
DNA loss at 9p21 (1.0% in both never and ever smokers).
Although ever smokers aged ≥50 years had slightly more
cells with CNVs than never smokers aged <50 years, the
small difference (~0.5%) was not significant (data not
shown).
In addition to the individual differences of each sub-
ject, urine density also influenced the detection of CNVs
in exfoliated urothelial cells. Cells in the voided urine
that had low creatinine content (<0.5 g/L) containedincreased amount of both DNA gain and loss, compared
with cells exfoliated into urine with creatinine concen-
tration ≥0.5 g/L. The corresponding figures for cells with
polysomy of chromosome 7 were 1.9% vs. 1.0%.
Table 5 shows the effect estimates from a GEE model
that examined factors which may influence the incidence
of CNVs in cells from tumor-free men. A low urinary cre-
atinine concentration had the strongest effect on detecting
deviations from the diploid karyotype that was assessed as
polysomy in at least one of the chromosomes 3, 7, and 17
or a DNA loss at the 9p21 locus (exp ðβ^Þ = 1.58 (95% con-
fidence interval (CI) 1.34 – 1.86) for creatinine <0.5 g/L as







CNV< 2 9p21 CNV > 2 of
chromosome




(95% CI)a exp β^
 
(95% CI)a exp β^
 
(95% CI)a exp β^
 
(95% CI)a exp β^
 
(95% CI)a
Creatinine < 0.5 g/L ≥ 0.5 g/L 1.69 (1.31 – 2.18) 1.73 (1.35 – 2.23) 1.53 (1.18 – 1.97) 1.40 (1.12 – 1.74) 1.58 (1.34 – 1.86)
Leukocytesb Present None or tracesb 0.95 (0.58 – 1.56) 0.94 (0.58 – 1.52) 0.88 (0.52 – 1.48) 0.78 (0.52 – 1.16) 0.85 (0.62 – 1.17)
Haematuriab Present None or tracesb 0.78 (0.59 – 1.04) 0.78 (0.59 – 1.02) 0.75 (0.56 – 0.99) 0.99 (0.80 – 1.24) 0.89 (0.75 – 1.05)
Age (years) 50 – <60 <50 1.54 (1.11 – 2.13) 1.57 (1.14 – 2.15) 1.50 (1.10 – 2.06) 1.22 (0.95 – 1.56) 1.30 (1.06 – 1.59)
60 – <70 <50 1.24 (0.92 – 1.67) 1.26 (0.95 – 1.68) 1.37 (1.02 – 1.82) 1.21 (0.97 – 1.50) 1.20 (1.00 – 1.43)
≥ 70 <50 1.45 (1.04 – 2.03) 1.55 (1.11 – 2.16) 1.74 (1.23 – 2.45) 1.24 (0.93 – 1.66) 1.31 (1.06 – 1.62)
Smoking Ever Never 1.26 (0.98 – 1.62) 1.27 (0.99 – 1.64) 1.33 (1.05 – 1.70) 1.11 (0.92 – 1.34) 1.14 (0.97 – 1.32)
aEffect estimates as factors from a generalized estimating equations model with built-in Poisson distribution.
bNone or traces if ≤5 cells per visual field microscopically and dipstick testing negative or <5 leukocytes.
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nificant for all single probes. We further confirmed the age
effect after adjustment for creatinine and other factors.
More cells with CNVs could be observed in the urine from
men aged ≥50 years as compared with younger men. How
ever, there was no further accumulation of CNVs by age
(50 – <60 years: exp ðβ^Þ = 1.30, 60 – <70 years: exp ðβ^Þ =
1.20, ≥70 years: exp ðβ^Þ = 1.31). The effect of age on DNA
loss was less pronounced than on DNA gain. The influ-
ence of ever smoking on CNVs was only marginal, with
exp ðβ^Þ = 1.14 (95% CI 0.97 – 1.32) for all probes, only
achieving significance for polysomy of chromosome 17
(exp ðβ^Þ = 1.33, 95% CI 1.05 – 1.70). The presence of urin-
ary leukocytes or erythrocytes seemed to impair the detec-
tion of CNVs in urothelial cells, which was statistically
significant for detecting polysomy of chromosome 17.Discussion
DNA copy number variations in exfoliated urothelial cells
from bladder tumor cases and tumor-free men
Genomic instability is a hallmark of cancer [25,26],
where aneuploidy is a common feature of tumorigenesis
(e.g. [4,27]). We assessed CNVs as numerical changes of
the chromosomes 3, 7, and 17, and of the 9p21 locus in
nearly 200,000 exfoliated urothelial cells from 1,595 male
participants of the UroScreen study. In previous ana-
lyses, we qualitatively assessed the extent of CNVs as ei-
ther a positive or negative result of the UroVysion™ test
that is normally used for bladder cancer screening
[18,23]. Here, we quantitatively analyzed CNVs in order
to explore the accumulation of CNVs during the devel-
opment of bladder tumors in serial pre-diagnostic samples
collected from cases. CNVs were rare three or more years
before the diagnosis of bladder cancer and in exfoliated
cells from papilloma cases. Loss of both alleles at 9p21was detected as an early event but without further accu-
mulation. In contrast, the fraction of cells with CNV > 2
continued to increase up to the time of diagnosis, with
more cells affected in cases with high-grade than low-
grade bladder cancer. The extent of DNA gain but not of
loss produced a positive result in the UroVysionTM test,
usually not earlier than in the year before diagnosis
[18,19]. Also, urine sediments from tumor-free men con-
tained about 1% cells with CNVs. We found slightly more
affected cells in men ≥50 years old, and considerably more
cells with CNVs in urine samples where the creatinine
concentration was <0.5 g/L.
The aneuploidy status of late-stage tumors provides
little information about the temporal accumulation of
genomic alterations during tumor development [10]. An
inadequate supply of human tissues from early disease
stages due to the lack of serial pre-diagnostic samples
from prospective studies is a severe limitation for cancer
research [28,29]. The main advantage of UroScreen is
the prospective design and a database compiling CNVs
in all single cells that were measured with UroVysion™.
This allowed us to assess the accumulation of CNVs
until diagnosis of bladder tumor. A general limitation is
the low incidence of bladder tumors in asymptomatic
subjects [23,30]. Further, the preference of morphologic-
ally aberrant cells for assessing CNVs according to the
protocol of the manufacturer may overestimate the ex-
tent of genomic alterations [19,23].
Tetrasomy in the development of bladder cancer
Cancer is characterized by uncontrolled cell growth,
where mitotic failure may occur, leading to tetraploidiza-
tion as an early event in tumorigenesis [5]. Tetraploidy
may therefore indicate a higher proliferation rate as well
as failure of cytokinesis [5]. Affected cells do not accur-
ately segregate whole chromosomes. The UroVysion™
Bonberg et al. BMC Cancer 2014, 14:854 Page 7 of 10
http://www.biomedcentral.com/1471-2407/14/854assay allows the determination of aneusomy of chromo-
somes 3, 7, and 17 with three probes designed for
centromere-specific sequences. Tetrasomy was the most
commonly observed CNV in cases as well as in tumor-
free men from UroScreen. In cases, we observed more
cells with tetrasomy starting three years before diagnosis,
compared to earlier samples or tumor-free men. The
fraction of exfoliated cells with CNV = 4 increased by
the degree of malignancy up to the time of diagnosis,
reaching 2.4% in papillomas, 4% in low-grade bladder
cancer, and 10% in high-grade bladder cancer. Notably,
tetrasomy of these three chromosomes occurred in par-
allel in cells isolated from cases as well as from tumor-
free men, indicating tetraploidy.
Aneusomy of chromosomes 3, 7 and 17 during cancer
development
Tetraploid cells are prone to additional numerical and
structural aberrations commonly defined as aneuploidy
[27], and other forms of genomic instability [5,31,32].
The fraction of cells with trisomy of chromosomes 3, 7,
or 17 increased from 0.3%-0.4% in tumor-free men, and
up to 4%-5% in cases with bladder cancer when ap-
proaching time of diagnosis. Also, CNV ≥5 occurred in
cases with a maximum of 10 copy numbers detected in
exfoliated cells. The amount of exfoliated cells that accu-
mulated gains was higher in high-grade bladder cancer
compared to low-grade bladder cancer, whereas aneus-
omy was not detected in cells from any of the papilloma
cases. Monosomy was rare and showed no clear increase
during cancer development. Former statistical analyses
on the UroVysion™ data, which were performed to im-
prove the tumor test, demonstrated that CNVs of chro-
mosomes 3, 7, and 17 were strongly correlated [19].
Deletion at 9p21 during cancer development
Besides alterations in the number of chromosomes, struc-
tural aberrations like the deletions of DNA sequences encod-
ing tumor suppressors or other cancer-related genes may
also occur during the development of cancer. For example,
loss of cyclin-dependent kinase inhibitor 1B (CDKN1B) has
been described in 23% of prostate cancers [33]. The 9p21
locus encompasses cyclin-dependent kinase inhibitor 2A
(CDKN2A), encoding p16 and p14 [14]. Loss of 9p21 has
been observed in bladder cancer and other malignancies
(e.g., [34,35]) and is considered an early step in the pro-
gression of urinary bladder carcinogenesis [36,37]. We
confirmed an increased rate of homozygous deletions
early in the development of bladder cancer. There was
rarely a loss of alleles in papilloma cases. Cases with
high-grade bladder cancer exhibited a larger percentage
of cells with loss at 9p21 compared to those with low-
grade bladder cancer. In line with another study [38], the
extent of DNA loss at 9p21 observed in UroScreen wasnot sufficient to achieve positivity of the UroVysion test
[19]. Weak signals of this probe may lead to false-negative
results [38].
Whereas malignancy has been associated with a complete
loss at 9p21, the impact of losing one allele is less clear
[39]. We observed 1.5% cells with CNV= 1 compared to
4% with a complete loss of 9p21 in cases prior to the diag-
nosis of bladder cancer. The corresponding figures were
0.6% and 0.4% in tumor-free men, respectively. A loss of
one allele may be combined with a mutation or hyperme-
thylation of the other allele and, therefore, a complete
loss of CDKN2A function cannot be captured by deter-
mining CNV alone [40]. However, point mutations or
hypermethylation at this locus may not be frequent in
bladder cancer [1].The distribution of DNA copy number variations in
exfoliated urothelial cells from tumor-free men
To our knowledge, we explored the largest collection of
FISH data in tumor-free subjects, although distributions
of similar datasets have been previously published [41,42].
More than 40% of all tumor-free men in UroScreen had at
least one cell with at least one CNV in repeatedly col-
lected urine samples. In line with a previous report [41],
we detected about 1% of cells with CNV > 2, mainly as tet-
rasomy. One explanation could be that some cells were in
S or G2 phase of the cell cycle [41]. We detected a similar
fraction of 1% of cells with CNV < 2 at 9p21. However, the
observed loss of DNA at this locus was lower compared
to other reports [41,42]. A small number of cells with
aneuploidy does not necessarily indicate cancer devel-
opment as previously suggested [41]. In addition, assay-
specific problems should be taken into account. For ex-
ample, two overlapping signals may appear as one, or
the hybridization of the probes was not efficient [41].The influence of age and smoking on the occurrence of
DNA copy number variations
Age is the strongest risk factor for the development of
cancer, with a steep rise of incidence after the age of
50 years. Aging may be accompanied by random alter-
ations of the genome that could accumulate and increase
the vulnerability for cancer-specific alterations [43]. Stud-
ies of the mitotic checkpoint regulator BubR1 demon-
strated the association between age and aneuploidization
[44]. We observed about 30% more cells with polysomy in
participants aged ≥50 years compared to younger men.
However, little is known about the age-related accumula-
tion of CNVs in sequences encoding for tumor suppres-
sors or oncogenes in humans. Cells with DNA loss at
9p21 seem not to accumulate with increasing age. It there-
fore appears plausible that the amplification or loss of
cancer-related genes has a higher probability of leading to
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during aging.
Although smoking is an established risk factor for devel-
oping cancer of the bladder [45], little is known about the
contribution of smoking to the development of chromo-
somal instability [13,14]. We observed slightly more cells
with CNVs in tumor-free men who reported having ever
smoked, but this was of marginal significance. A more
precise assessment of smoking behavior would be neces-
sary to refine a potential effect of smoking on the develop-
ment of genomic alterations.
Exfoliation of urothelial cells with copy number
variations – also a clearance mechanism?
During the assessment of the performance of the UroVy-
sion™ test, we observed that considerably more aberrant
cells were detected in urine samples from cases with a
low creatinine content [22]. Here, we could demonstrate
a similar and strong effect in this large group of tumor-
free subjects. Approximately twofold more cells with
CNVs were detected in diluted urine with creatinine
concentrations <0.5 g/L. The interpretation of this effect
is challenging. Assay-specific problems may occur in
samples with higher cellularity [41]. Furthermore, low
osmolarity in diluted urine may impair the hybridization
efficiency of UroVysion™ probes. Another hypothesis is
that urothelial cells with mitotic failure are exfoliated at
a higher rate as a clearance mechanism in order to avoid
the accumulation of genomic alterations in the target
tissue [9].
The instillation of urinary tract infections is increas-
ingly applied as a form of effective immunotherapy to
better eliminate cancer cells from the urothelium [46].
Cell death following aberrant mitosis or other damaging
events may be initiated to avoid persistence of genomic
instability [7]. Apoptosis and other senescence mecha-
nisms can “clear” the target tissue from genomic alter-
ations. The sensitivity of cancer cells to therapeutic agents
might stimulate this clearance. We observed that in cases
after diagnosis, the fraction of cells with CVNs was still
twice the average level to those measured in tumor-free
men. However, the exfoliation of damaged cells may also
be explained by the high recurrence rate of bladder tu-
mors indicating the development of a subsequent tumor.
Conclusions
We observed an accumulation of CNVs in exfoliated
urothelial cells assessed with polysomy of chromosomes
3, 7, and 17 and loss at 9p21 during the development of
bladder cancer in serial pre-diagnostic samples from
cases. High-grade bladder cancer was associated with
more DNA loss and gain than low-grade bladder cancer,
whereas CNVs were rarely found in exfoliated cells from
papilloma cases. CNVs were higher in cases as early asthree years before diagnosis compared with tumor-free
men, but the extent required for a positive UroVysion™
test is usually achieved no earlier than a year before
diagnosis. This should be considered when using the test
for the early detection of bladder cancer. We also ob-
served elevated CNVs in screening rounds after diag-
nosis. Whether this indicates a recurrent bladder cancer
or the clearance of the target tissue from damaged cells
fostered by immunotherapy remains to be investigated.
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